QCLS Stock — Q/C Technologies Inc.: Cash, EV, Pipeline

What they do

The Company’s core strategy is centered on leveraging an exclusive global licensing agreement with LightSolver Ltd. (“LightSolver”) to deploy innovative laser processing units (“LPUs”), including the Company-branded qc-LPU100™ (the “qc-LPU100”). These systems are designed to harness the natural properties of light to perform complex computations with the goal of achieving high computational speed and improved energy efficiency relative to traditional computing architectures.

Source: 10-K FY2025 via SEC EDGAR

Share price

$0.34

Market cap

$2.8M

Cash

$11.0M

Enterprise value

-$8.2M

Balance sheet

Cash	$11.0M
Debt	$0.0M
Net cash	$11.0M
Enterprise value	-$8.2M
Basic shares	8.2M shares
Fully diluted shares	12.1M shares
Fully diluted market cap	$4.1M
Cash per share	$1.34
Quarterly burn	$1.8M
Cash runway	6.0 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

8.2M

Pre-funded warrants

0.0M

Options

0.4M

RSUs

—

Warrants

—

Converts

—

Conv preferred

3.5M

ESPP reserve

0.0M

FDSO

12.1M

Cap table as of 2026-08-12.

Price history

Loading QCLS daily closes…

Loading price history…

Upcoming catalysts

No upcoming catalysts on file for this company.

Full readout calendar →

Pipeline assets

Isomyosamine

Phase 2 · Active Modality: small molecule (oral)

Aliases MYMD-1

Target TNF-α

Indications

not disclosed (Phase 2)

Status note Oral next-generation TNF-α inhibitor; Phase 2b study suspended (development costs fell sharply in 2026). Company resources redirected to laser-based and optical computing (qc-LPU100/LPU); evaluating strategic alternatives for the legacy pharmaceutical programs including divestiture, partnering or licensing.

Supera-CBD

Stage not disclosed · Active

Indications

not disclosed (Stage not disclosed)

Status note Legacy pharmaceutical product candidate alongside Isomyosamine; no stage, target or indication stated in excerpts. Company is a party to manufacture/formulation agreements for Supera-CBD and MIRA1a; evaluating strategic alternatives for legacy programs.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	50,000	no change	0.01%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

QCLS — Q/C Technologies Inc. ☆